MLMC Therapeutics ApS: Financial statements 2021
CVR: 41277688
Source: annual report 2021, Danish Business Authority
01/01/2021 – 31/12/2021
MLMC Therapeutics ApS (CVR 41277688) has filed annual accounts for 2021. In 2021, the company reported a gross profit of DKK -19,909 and a net result of DKK -53,670. Equity in the 2021 report amounted to DKK 8,369. The solvency ratio was 4.7%.
- Gross Profit
- DKK -19,909
- Profit/Loss
- DKK -53,670
- Equity
- DKK 8,369
- Total Assets
- DKK 176,443
- Employees
- 0
Official annual report
Find more companies like MLMC Therapeutics ApS
Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.
Try the lead list generatorEvents in 2021
As of September 30, 2021, Ritika Singh Petersen is registered as an owner of MLMC Therapeutics ApS with an ownership share of 5%.
As of September 30, 2021, Sriram Thoppe Rajendran is registered as an owner of MLMC Therapeutics ApS with an ownership share of 5%.
MLMC Therapeutics ApS has published its interim report for the period April 3, 2020 – December 31, 2020.
About MLMC Therapeutics ApS
MLMC Therapeutics ApS is a Danish company of the type Anpartsselskab based in Kastrup, founded in 2020. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Michael Henrik Stadi. The board consists of Martin Kiener (chair), Hanne Damgaard Jensen and Peter Gudmund Nielsen. The company's owners include Ritika Singh Petersen, Sriram Thoppe Rajendran and FOMT HOLDING ApS. According to the 2021 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -30,768 and a net result of DKK -144,214 compared with DKK -134,525 the year before. Equity in the 2025 report amounted to DKK -483,287.